BrainsWay Ltd. (NASDAQ:BWAY - Free Report) - Research analysts at HC Wainwright boosted their Q2 2025 EPS estimates for shares of BrainsWay in a research report issued on Tuesday, May 27th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.05 per share for the quarter, up from their previous forecast of $0.04. HC Wainwright has a "Buy" rating and a $16.00 price objective on the stock. The consensus estimate for BrainsWay's current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for BrainsWay's FY2025 earnings at $0.19 EPS.
BrainsWay (NASDAQ:BWAY - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.02. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. The company had revenue of $11.54 million for the quarter, compared to analysts' expectations of $11.45 million.
BrainsWay Trading Down 0.4%
Shares of NASDAQ:BWAY traded down $0.04 during trading on Thursday, reaching $10.16. The stock had a trading volume of 17,032 shares, compared to its average volume of 67,716. BrainsWay has a one year low of $5.67 and a one year high of $11.79. The company has a market capitalization of $191.74 million, a P/E ratio of 101.61 and a beta of 1.25. The firm's 50-day simple moving average is $9.23 and its 200 day simple moving average is $9.73.
Institutional Trading of BrainsWay
Institutional investors have recently modified their holdings of the company. Two Sigma Investments LP raised its position in shares of BrainsWay by 2.0% in the 4th quarter. Two Sigma Investments LP now owns 92,755 shares of the company's stock valued at $875,000 after purchasing an additional 1,786 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of BrainsWay by 10.8% during the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company's stock valued at $207,000 after purchasing an additional 2,144 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of BrainsWay by 14.6% during the 4th quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company's stock valued at $181,000 after purchasing an additional 2,446 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in BrainsWay in the 4th quarter worth $44,000. Finally, NewEdge Advisors LLC increased its holdings in BrainsWay by 61.5% in the 1st quarter. NewEdge Advisors LLC now owns 19,828 shares of the company's stock worth $188,000 after acquiring an additional 7,549 shares in the last quarter. 30.11% of the stock is currently owned by institutional investors.
BrainsWay Company Profile
(
Get Free Report)
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Read More
Before you consider Brainsway, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brainsway wasn't on the list.
While Brainsway currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
